Mary B. Todd
About
Mary B. Todd is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology.
According to data from OpenAlex, Mary B. Todd has authored 54 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 24 papers in Radiology, Nuclear Medicine and Imaging and 18 papers in Oncology. Recurrent topics in Mary B. Todd's work include Prostate Cancer Treatment and Research (36 papers), Radiopharmaceutical Chemistry and Applications (22 papers) and Prostate Cancer Diagnosis and Treatment (11 papers). Mary B. Todd is often cited by papers focused on Prostate Cancer Treatment and Research (36 papers), Radiopharmaceutical Chemistry and Applications (22 papers) and Prostate Cancer Diagnosis and Treatment (11 papers). Mary B. Todd collaborates with scholars based in United States, France and United Kingdom. Mary B. Todd's co-authors include Karim Fizazi, Peter De Porre, Thian Kheoh, Kim N., Nobuaki Matsubara, Andrew Protheroe, A. Rodrı́guez-Antolı́n, Luis Fein, Youn C. Park and B. Yа. Alekseev and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Mary B. Todd
51 papers receiving 2.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mary B. Todd United States | 18 | 2.1k | 739 | 691 | 605 | 428 | 54 | 2.5k | ||
| Daniel Petrylak United States | 6 | 1.9k 0.9× | 726 1.0× | 592 0.9× | 813 1.3× | 453 1.1× | 8 | 2.4k | ||
| De Phung United States | 19 | 1.7k 0.8× | 618 0.8× | 612 0.9× | 495 0.8× | 289 0.7× | 46 | 2.0k | ||
| Peter De Porre United States | 26 | 2.5k 1.2× | 893 1.2× | 854 1.2× | 761 1.3× | 730 1.7× | 91 | 3.4k | ||
| Susan Feyerabend United Kingdom | 21 | 3.2k 1.5× | 1.0k 1.4× | 1.1k 1.6× | 1.0k 1.7× | 726 1.7× | 71 | 3.9k | ||
| Liji Shen United States | 16 | 2.8k 1.3× | 1.1k 1.5× | 946 1.4× | 1.3k 2.1× | 620 1.4× | 37 | 3.5k | ||
| David Lorente Spain | 28 | 1.8k 0.9× | 653 0.9× | 1.1k 1.5× | 1.2k 2.0× | 594 1.4× | 100 | 2.9k | ||
| Diletta Bianchini United Kingdom | 22 | 1.6k 0.8× | 755 1.0× | 768 1.1× | 659 1.1× | 356 0.8× | 68 | 2.1k | ||
| Bryan Selby United States | 5 | 3.3k 1.5× | 1.1k 1.5× | 1.0k 1.5× | 917 1.5× | 848 2.0× | 11 | 3.7k | ||
| Shinta Cheng United States | 13 | 1.3k 0.6× | 537 0.7× | 432 0.6× | 441 0.7× | 257 0.6× | 39 | 1.6k | ||
| Julie S. Larsen United States | 13 | 1.3k 0.6× | 494 0.7× | 416 0.6× | 322 0.5× | 303 0.7× | 31 | 1.8k |
Countries citing papers authored by Mary B. Todd
Since
Specialization
Citations
This map shows the geographic impact of Mary B. Todd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary B. Todd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary B. Todd more than expected).
Fields of papers citing papers by Mary B. Todd
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mary B. Todd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary B. Todd. The network helps show where Mary B. Todd may publish in the future.
Co-authorship network of co-authors of Mary B. Todd
This figure shows the co-authorship network connecting the top 25 collaborators of Mary B. Todd. A scholar is included among the top collaborators of Mary B. Todd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary B. Todd. Mary B. Todd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
N., Kim, Andrew Protheroe, A. Rodrı́guez-Antolı́n, et al.. (2018). Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. The Lancet Oncology. 19(2). 194–206.
2.
Fizazi, Karim, Luis Fein, Nobuaki Matsubara, et al.. (2017). Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 377(4). 352–360.
3.
Smith, Matthew R., Fred Saad, Dana E. Rathkopf, et al.. (2017). Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology. 72(1). 10–13.
4.
Fizazi, Karim, Kim N., Johann S. de Bono, et al.. (2016). Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 70(3). 438–444.
5.
Cella, David, Susan Li, Tracy Li, et al.. (2016). Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. The Journal of Community and Supportive Oncology. 14(4). 148–154.
6.
Flaig, Thomas W., et al.. (2016). Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database. Clinical Genitourinary Cancer. 15(2). 273–279.e1.
7.
Bono, Johann S. de, Matthew R. Smith, Fred Saad, et al.. (2016). Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology. 71(4). 656–664.
8.
Scher, Howard I., et al.. (2015). Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE. 10(10). e0139440–e0139440.
9.
Sternberg, Cora N., Daniel Castellano, Gedske Daugaard, et al.. (2014). Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet Oncology. 15(11). 1263–1268.
10.
Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2014). ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.. Journal of Clinical Oncology. 32(15_suppl). 5026–5026.
11.
Goodin, Susan, Kamakshi V. Rao, Michael D. Kane, et al.. (2005). A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 56(2). 199–204.
12.
Todd, Mary B.. (2004). Meperidine and the Management of Pain. Lippincott s Case Management. 9(5). 240–241.
13.
Kaufman, Donald S., Michael A. Carducci, Mary B. Todd, et al.. (2004). A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urologic Oncology Seminars and Original Investigations. 22(5). 393–397.
14.
Motzer, Robert J., Robert J. Amato, Mary B. Todd, et al.. (2003). Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma. Investigational New Drugs. 21(1). 99–101.
15.
DiPaola, Robert S., Weichung Joe Shih, Yong Lin, et al.. (2001). Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 92(8). 2065–2071.
16.
Mani, Sridhar, et al.. (1996). Recombinant Beta-Interferon in the Treatment of Patients with Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 19(2). 187–189.
17.
Buzaid, Antônio C., Giuseppe Pizzorno, John C. Marsh, et al.. (1995). Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. Cancer Chemotherapy and Pharmacology. 36(5). 373–378.
18.
Mani, Sridhar, et al.. (1995). Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers. The Journal of Urology. 35–40.
19.
Wiernik, Peter H., et al.. (1994). Polyethylene glycolated interleukin‐2 as maintenance therapy for acute myelogenous leukemia in second remission. American Journal of Hematology. 47(1). 41–44.
20.
Bach, R, et al.. (1993). Synthesis of tissue factor messenger rna and procoagulant activity in breast cancer cells in response to serum stimulation. Thrombosis Research. 72(2). 155–168.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Daniel Petrylak Breakdown of academic impact, for papers by De Phung Breakdown of academic impact, for papers by Peter De Porre Breakdown of academic impact, for papers by Susan Feyerabend Breakdown of academic impact, for papers by Liji Shen Breakdown of academic impact, for papers by David Lorente Breakdown of academic impact, for papers by Diletta Bianchini Breakdown of academic impact, for papers by Bryan Selby Breakdown of academic impact, for papers by Shinta Cheng Breakdown of academic impact, for papers by Julie S. Larsen